Skip to main content

A Multi-Plaintiff Essure Lawsuit Remanded Back to State Court

A Multi-Plaintiff Essure Lawsuit Remanded Back to State Court

 A Multi-Plaintiff Essure Lawsuit Remanded Back to State Court

Introduction

On April 23, U.S. District Judge Karen Caldwell remanded a multi-plaintiff Essure lawsuit to Pike Circuit Court, Kentucky, where it was originally filed stating the case didn’t violate any substantial federal law and the claims made were non-diverse.

The case was filed by a group of three women in March 2017 against Bayer and Pikeville Medical Center, after three of them suffered similar injuries post Essure birth control device implantation at the same medical center.

Bayer managed to transfer the case to the federal court system on the grounds that federal question and diversity jurisdiction applied. The plaintiffs opposed the transfer and requested for the case to be transferred back to the state.

Judge Caldwell sided the plaintiffs stating, ‘’the defendants failed to carry out the burden of proving that the Kentucky statute of limitations prevented the plaintiffs from having a colorable basis of recovery under Kentucky law.”

Comments

Restricted HTML

  • Allowed HTML tags: <a href hreflang> <em> <strong> <cite> <blockquote cite> <code> <ul type> <ol start type> <li> <dl> <dt> <dd> <h2 id> <h3 id> <h4 id> <h5 id> <h6 id>
  • Lines and paragraphs break automatically.
  • Web page addresses and email addresses turn into links automatically.

Latest News

First Federal Bellwether Trial Set in Strattice Mesh Case

Categories: Hernia Mesh

Lawyers involved in federal Strattice hernia mesh litigation are scheduled to meet with the presiding judge in the U.S. District Court for the District of New Jersey to…

Tepezza Hearing Loss Trial Set for June 2026

Categories: Tepezza

The U.S. District Judge overseeing all federal Tepezza lawsuits has postponed the start of the first bellwether trial by 60 days.

This decision comes as attorneys…

FDA Moves to Restrict Dangerous 7-OH Opioid Products

Categories: Opioids

In a significant move to combat the ongoing opioid crisis, the U.S. Food and Drug Administration (FDA) has recommended a scheduling action under the Controlled Substances Act (CSA) to regulate certain products containing 7-hydroxymitragynine (7-…

✍️ FREE — 2,800 Pages Legal Process Outsourcing Trial!                 
No Contract. No Risk — Full Mass Tort + LPO Access, Free!

Only 10 Firms Accepted—Offer Ends August 31!